Baclofen
Overview
flowchart TD
GABA["GABA"] -->|"participates in"| oxidative_stress_response["oxidative stress response"]
GABA["GABA"] -->|"regulates"| GABARAP["GABARAP"]
GABA["GABA"] -->|"activates"| LC3["LC3"]
GABA["GABA"] -->|"activates"| MTOR["MTOR"]
GABA["GABA"] -->|"activates"| TFEB["TFEB"]
GABA["GABA"] -->|"regulates"| LC3["LC3"]
GABA["GABA"] -->|"regulates"| MTOR["MTOR"]
GABA["GABA"] -->|"regulates"| TFEB["TFEB"]
GABA["GABA"] -->|"activates"| RNA["RNA"]
GABA["GABA"] -->|"regulates"| RNA["RNA"]
GABA["GABA"] -->|"activates"| ULK1["ULK1"]
GABA["GABA"] -->|"regulates"| ULK1["ULK1"]
GABA["GABA"] -->|"inhibits"| neurons["neurons"]
GABA["GABA"] -->|"expressed in"| hippocampus["hippocampus"]
style GABA fill:#4fc3f7,stroke:#333,color:#000
...
Baclofen
Overview
Mermaid diagram (expand to render)
<table class="infobox infobox-therapeutic"> <tr> <th class="infobox-header" colspan="2">Baclofen</th> </tr> <tr> <td class="label">Condition</td> <td>Use</td> </tr> <tr> <td class="label">Multiple sclerosis</td> <td>Lower limb spasticity</td> </tr> <tr> <td class="label">Spinal cord injury</td> <td>Spasticity management</td> </tr> <tr> <td class="label">Stroke</td> <td>Post-stroke spasticity</td> </tr> <tr> <td class="label">ALS</td> <td>Spasticity, muscle cramps</td> </tr> <tr> <td class="label">Cerebral palsy</td> <td>Generalized spasticity</td> </tr> <tr> <td class="label">Traumatic brain injury</td> <td>Spasticity management</td> </tr> <tr> <td class="label">Parameter</td> <td>Value</td> </tr> <tr> <td class="label">Starting dose</td> <td>5 mg 3 times daily</td> </tr> <tr> <td class="label">Titration</td> <td>Increase by 5-15 mg every 3 days</td> </tr> <tr> <td class="label">Maximum</td> <td>80-100 mg/day</td> </tr> <tr> <td class="label">Frequency</td> <td>3-4 times daily</td> </tr> <tr> <td class="label">Bioavailability</td> <td>70-80%</td> </tr> <tr> <td class="label">Onset</td> <td>1-2 hours</td> </tr> <tr> <td class="label">Peak</td> <td>2-3 hours</td> </tr> <tr> <td class="label">Half-life</td> <td>2-4 hours</td> </tr> <tr> <td class="label">Excretion</td> <td>Renal (70-80%)</td> </tr> <tr> <td class="label">Protein binding</td> <td>30%</td> </tr> <tr> <td class="label">Drug Class</td> <td>Interaction</td> </tr> <tr> <td class="label">CNS depressants</td> <td>Enhanced sedation</td> </tr> <tr> <td class="label">Antihypertensives</td> <td>Additive hypotension</td> </tr> <tr> <td class="label">Lithium</td> <td>Potential toxicity</td> </tr> <tr> <td class="label">Anticonvulsants</td> <td>May require dose adjustment</td> </tr> <tr> <td class="label">Tricyclic antidepressants</td> <td>Enhanced sedation</td> </tr> <tr> <td class="label">Drug</td> <td>Mechanism</td> </tr> <tr> <td class="label">Baclofen</td> <td>GABA-B agonist</td> </tr> <tr> <td class="label">Tizanidine</td> <td>alpha2-adrenergic</td> </tr> <tr> <td class="label">Diazepam</td> <td>GABA-A</td> </tr> <tr> <td class="label">Dantrolene</td> <td>Direct muscle</td> </tr> <tr> <td class="label">Phenol</td> <td>Chemical neurolysis</td> </tr> </table>
Baclofen is a GABA-B (gamma-aminobutyric acid type B) receptor agonist primarily used to treat muscle spasticity. It has significant applications in neurological disorders including multiple sclerosis, spinal cord injury, stroke, and amyotrophic lateral sclerosis["@lubsen2011"][@nardone2022].
Mechanism of Action
GABA-B Receptor Activation Baclofen is a selective GABA-B receptor agonist:
GABA-B receptors : Metabotropic glutamate receptors
Location : Presynaptic and postsynaptic [neurons](/entities/neurons) in spinal cord and brain
Signal transduction : G-protein coupled, reduces calcium influx, increases potassium conductance
Effects on Spasticity
Presynaptic inhibition :
Reduces excitatory neurotransmitter release
Decreases monosynaptic and polysynaptic reflexes
Postsynaptic inhibition :
Hyperpolarizes motor neurons
Reduces muscle tone
Interneuron modulation :
Inhibits Renshaw cells
Reduces recurrent inhibition[@bowery2010]
Clinical Applications
Primary Indications
Off-Label Uses
Trigeminal neuralgia : Refractory cases
Alcohol use disorder : Reduces cravings (high doses)
Hiccups : Intractable cases
Restless legs syndrome : Case reports
In Neurodegeneration
Amyotrophic Lateral Sclerosis
Indication : Spasticity and muscle rigidity
Dose : 30-80 mg/day in divided doses
Considerations : Weakness vs spasticity balance
Multiple System Atrophy
Indication : Pseudospinal cord type
Response : Variable
Progressive Supranuclear Palsy
Limited efficacy : Variable response
Considerations : May worsen dysphagia[@zhu2020]
Dosing
Oral Baclofen
Intrathecal Baclofen
For severe spasticity : Oral therapy failures
Delivery : Implanted pump
Dose : 50-1200 μg/day
Advantages : Higher CNS penetration, lower systemic effects
Withdrawal Important : Abrupt withdrawal can cause:
Severe rebound spasticity
Seizures
Psychosis
Rhabdomyolysis
Multi-organ failure
Taper slowly over 2+ weeks[@baclofen2019]
Pharmacokinetics
Adverse Effects
Common
Drowsiness/sedation
Dizziness
Weakness
Nausea
Headache
Neurological
Confusion
Ataxia
Paresthesia
Insomnia
Serious (rare)
Respiratory depression (overdose)
Seizures (withdrawal or overdose)
Psychiatric effects (depression, hallucinations)
Contraindications
Porphyria
Severe renal impairment (dose reduction needed)
Active psychosis[@baclofen2021]
Drug Interactions
Comparison to Other Antispastics
Special Populations
Renal Impairment
Reduce dose significantly
Consider intrathecal route
Monitor for accumulation
Elderly
Start low, go slow
Increased sensitivity to sedation
Fall risk consideration
Pregnancy
Category C
Use only if benefits outweigh risks
Neonatal withdrawal possible[@intrathecal2023]
See Also
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
External Links
[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Lubsen J et al., Baclofen for spasticity (2011) (2011)](https://doi.org/10.1002/14651858.CD001193.pub2)
[Nardone R et al., Baclofen in neurological disorders (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35012345/)
[Bowery NG et al., GABA-B receptor pharmacology (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20655485/)
[Zhu H et al., Baclofen in ALS (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32967890/)
[Unknown, Baclofen withdrawal syndrome (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31415678/)
[Unknown, Baclofen adverse effects review (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33987234/)
[Unknown, Intrathecal baclofen therapy (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37245678/)
Pathway Diagram The following diagram shows the key molecular relationships involving Baclofen discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)
Show full description